Shooting for the 18TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY

Transcription

1 Shooting for the Stars Entering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine 18TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY BioPaciffiic Conference 2016 太 平 洋 生 物 大 会 18th CABS Annual Conference May 7th, Saturday, 2016, 8:00AM-9:00PM San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402

2 BIOPACIFIC CONFERENCE 2016 SPONSORS Diamond Platiumn Gold Silver Alliance and Promotional Partners 2

3 CABS Contact Information 中 美 药 协 联 系 信 息 Mailing Address 邮 政 地 址 268 Bush Street, #1888 San Francisco, CA 94104, USA Website 网 页 地 址 Our Mission To serve biopharmaceutical professionals with interests in China and promote interactions locally and across the Pacific 为 有 意 在 中 国 创 业 经 商 的 专 业 人 士 提 供 本 地 及 跨 太 平 洋 的 合 作 机 会 To foster business opportunities and exchanges in the life science industry between the U.S. and China 促 进 中 美 生 物 医 药 交 流 和 商 业 合 作 To promote public awareness of progress and development in the pharmaceutical and biotechnological industry 提 高 公 众 对 生 物 技 术 及 制 药 行 业 新 进 展 的 了 解 To collaborate with other organizations in areas of mutual interest 与 其 它 机 构 和 组 织 发 展 互 利 合 作 关 系 电 子 邮 件 信 箱 General information 一 般 信 息 Membership 会 员 申 请 Fundraising 募 款 Brochure Design 会 议 手 册 设 计 Xiaojun Li Brochure Production 会 议 手 册 制 作 CABS Publication Committee

4 Shooting for the Stars TABLE OF CONTENTS 2 BioPacific Conference 2016 Sponsors and Partners 3 Our Mission CABS Contact Information 4 Table of Contents 6 CABS Leadership BioPacific Conference Organizing Committee 8 About CABS 9 Remarks from the President of CABS 10 CABS Membership Facts 11 Inaugural BioPacific Partnering Forum 12 BioPacific Conference 2016 Agenda 14 Speakers Gerald Chan, Sc.D. Hari Kumar, Ph.D. Piers Whitehead Robert Lou Hui Zhang, Jinqun Yin, MBA Mark Selby, Ph.D. Stanley Lei Qi, Ph.D. Darren Ji, M.D., Ph.D., MBA Charles Comey, J.D. Thomas L. Irving, J.D. Wen Li, Ph.D. Shawn Qian, Ph.D. 4

5 Chinese American Biopharmaceutical Society BIOPACIFIC CONFERENCE Xian-Ping Lu, Ph.D. Dan Zhang, M.D., Ph.D. Xiaodong Yang, M.D., Ph.D. Cheni Kwok, Ph.D., CLP Connie Sun, Ph.D. Steven Adams, DVM, Ph.D. Min Cui, Ph.D. Alexis Ji, Ph.D., MBA Shawn Lee, Ph.D. Cheng Liu, Ph.D. Vincent Liu, Ph.D. Yuwen Liu James Zhao, M.D. Jennifer Hu, Ph.D CABS K. Fong Award in Life Sciences 38 CABS Activities Highlight of Past Events with Our Partners Science & Technology Programs Business & Career Development International Collaboration Social Life Membership 50 Advertisements 63 CABS Membership/Sponsorship Benefits *The official working language of the conference is English 5

6 Shooting for the Stars CABS Leadership Board of Directors Alan Hao, Ph.D. Jing-Shan Hu, Ph.D. Leping Li, Ph.D. Shichang Miao, Ph.D. Zhonghua Pei, Ph.D. Jun Xiang, Ph.D. Janet Xiao, Ph.D., J.D. Naibo Yang, Ph.D. Wentao Zhang, Ph.D. Advisory Board Wei Dong, M.D., Ph.D. Baolu Chen, Ph.D. Keting Chu, M.D., Ph.D. John Wang, Ph.D. Guoliang Yu, Ph.D. Cheng Li, Ph.D. DQ Wang, Ph.D. Yingfei Wei, Ph.D Executive Council President Jiangwen Majeti, Ph.D., M.B.A. Roche/Genentech President-Elect Cheni Kwok, Ph.D., CLP, Linear Dreams Past President Xiaolin Alan Hao, Ph.D., AIM Biosciences Inc. Treasurer David Wang, B.S., C.P.A. Bookkeeper Yao Long, B.S. Epitomics, Inc. Business & Career Development Co-chairs Jessica Sun, Ph.D. Reset Therapeutics Alex J. Zhang, Ph.D. Enverest, Inc. Elected Members Tim Tian, Ph.D. CelloBio Inc. Appointed Members/Volunteers Ting Jia, Ph.D. Jiangsu Hengrui Medicine Shenshen Hu, Ph.D. UC Berkeley Fundraising Co-chairs Jianlong Lou, Ph.D. UCSF Gavin Lu, Ph.D. Eureka Therapeutics Inc. Elected Members Charles Chen, Ph.D. Bellen Chemistry Norman Zhou, Ph.D. Genentech Appointed Members/Volunteers Li-Ming Liang, Ph.D. Nexcelom Bioscience International Collaboration Co-chairs Yan Wang, Ph.D. Gazelle Technologies Wei Zhang, Ph.D. Robotic Medsystems Elected Members Dannis Chang, Ph.D. Genentech Appointed Members/Volunteers Hao Wu, Ph.D. UCSF Lingjie Guan, Ph.D. Bayer Membership Co-chairs Liping Meng, Ph.D. Gilead Sciences Yonghua Pan, Ph.D. Sangamo Biosciences Elected Members Yan Qi, Ph.D. Morrison & Foerster LLP Lin Yan, Ph.D. Applied StemCells, Inc. Operations Chair Carrie Kaiyue Wang, M.D. Concept to Clinic Elected Members Zhican Wang, Ph.D. Amgen Appointed Members/Volunteers Yang Du, Ph.D. Stanford Publication & Communication Co-chairs Zhenhai Shen, Ph.D. Genentech Yang Tian, Ph.D. Gilead Sciences Elected Members Jieyi Wang, Ph.D. Abbvie Eva Wang, Ph.D. HTG Molecular Dx Xiang Wang, Ph.D. Denali Therapeutics Science & Technology Co-chairs Ann Mongan, Ph.D. Thermo Fisher Scientific Jiwen (Jim) Liu, Ph.D. RIFA Pharma, Inc. Elected Members Taotao Chen, Ph.D. Bayer Luqia Hou, Ph.D. Stanford Social Life Co-chairs Sihong Zhou, Sutro Biopharma Jian (Ken) Zhang, Ph.D. Pharmacyclics Elected Members Lynn Guo, Ph.D. Genentech 6

7 BIOPACIFIC CONFERENCE Biopacific Conference Organizing Committee Cheni Kwok, Ph.D., CLP, 2016 BioPacific Conference Chair; CABS President-Elect; Managing Partner, Linear Dreams Jiangwen Majeti, Ph.D., MBA, President CABS; Global Category Manager, Biomarker and CDx, Roche/Genentech Carrie Kaiyue Wang, M.D., CABS Operations Chair, Pre-clinical/Toxicology, Concept to Clinic Gavin (Jingwei) Lu, Co-Chair CABS Fundraising Committee; Research Scientist, Eureka Therapeutics Jianlong Lou, Co-Chair, CABS Fundraising Committee; Associate Professor, UCSF Yang Tian, Ph.D., Co-Chair, CABS Publication Committee; Research Scientist, Gilead Zhenhai Shen, Ph.D., MBA, Co-Chair CABS Publication Committee; Director, Research Service Procurement, Global Pharma Procurement, Genentech Liping Meng, Ph.D., Co-Chair CABS Membership Committee; Research Scientist Gilead Yonghua Pan, Ph.D., Co-Chair CABS Membership Committee; Scientist, Sangamo BioSciences Yan Wang, Ph.D., Co-Chair, CABS International Collaboration Committee; Vice President, Business Development, Gazelle Technologies Wei Zhang, Ph.D., Co-Chair, CABS International Collaboration, Project Manager, HBI Solutions Alex J. Zhang, Ph.D., MBA, Co-Chair CABS Business and Career Development Committee; Managing Partner, Enverest Jessica Sun, Ph.D., Co-Chair CABS Business and Career Development Committee; Director, In Vivo Biology; Reset Therapeutics Hao Wu, Ph.D., CABS International Collaboration Committee, Associate Specialist, UCSF Alexis Ji, Ph.D., MBA, Principal, WuXi Healthcare Ventures Shawn Qian, Ph.D., Co-Founder, Chief Executive Officer & President, NeuPharma Sihong Zhou, Ph.D. Co-Chair CABS Social Life Committee; Sutro Biopharma Jian (Ken) Zhang, Ph.D. Co-Chair CABS Social Life Committee; Pharmacyclics Special Acknowledgements: CABS Operations, Executive Committees and volunteers Ken Fong, Ph.D., Founder and Chairman, Kenson Ventures LLC Wentao Zhang, Ph.D., CABS BOD, Founder, Quintara Discovery Ruhong Jiang, Ph.D., CEO & President, Applied Stem Cells Charlene Liao, Ph.D., Project Team Leader, Genentech Shichang Miao, Ph.D., Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc. Mohan Srinivasan, Director, Protein Chemistry, Bristol-Myers Squibb Connie Sun, Ph.D., SVP, Business & Corporate Development, Pharmaron Minli Xie, Ph.D., Senior Director, Medivation Naibo Yang, Ph.D., Director, Immunogenetics at Complete Genomics Inc. Graphics and Websites: Xiaojun Li, Graphic Design/Website Design Michael Lin, Website Design & Support, Pink Trumpet Associates 7

8 Shooting for the Stars About CABS Who We Are The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in San Francisco Bay Area, California. This is the home of the Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and subscribers in the life sciences industry. About 70% of our members have Ph.D. degree relating to life sciences. A considerable proportion of the members are holding senior research and management positions in American and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in Northern America. We organize many activities to promote Sino-US collaborations in life sciences and to provide Science & Technology Parks and life sciences companies in China with an excellent platform to promote business and to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders. CABS Membership Demographics Our membership consists of life science professionals from a broad range of experience levels. A large percentage of our members hold senior or executive positions in the industry, and we are proud to have numerous entrepreneurs who have successfully started and sold life science companies in our pedigree. In addition, we continue to attract new talent from the local academic institutions (UC Berkeley, UC San Francisco, and Stanford University, among others). 8

9 BIOPACIFIC CONFERENCE Welcome to the 2016 BioPacific Conference, the 18th annual conference of the Chinese American Biopharmaceutical Society (CABS)! I would like to thank President-elect Dr. Cheni Kwok, the conference organization committee, and all the volunteers who have worked diligently for the past six months to bring you this impressive program. The biopharmaceutical industry has been experiencing tremendous growth in recent years. We have record high FDA new drug approvals, an active IPO market, and exciting Merger and Acquisition activities. Leading in biotech investment from venture capital firms, the San Francisco Bay Area prizes itself not only as a hot bed for innovation and start-ups, but also as a magnet for talent both of which have increasingly attracted attention from global companies including many in China. Our 18th annual conference will cover multiple aspects of these important trends. As one of the largest non-profit biopharmaceutical professional organizations on the west coast, CABS is uniquely positioned to ride the wave of biotech/pharmaceutical success. On one hand, we continue to serve our members by providing cutting-edge and educational Science and Technology workshops and nurturing the growth of next generation professionals with career-mentoring programs. On the other hand, we actively engage companies from China to support their talent recruitment activities and investment interests for novel technologies and pharmaceutical programs. To foster greater exchange between the biotech communities in both the US and China, we continue to organize annual delegation trips to China. Taking advantage of our San Francisco location, we successfully organized the first CABS Investor Forum 2016 at the JP Morgan conference to bridge an ongoing dialogue between investors and entrepreneurs across the Pacific Ocean. CABS s success is a story of a strong community with the support of many. We are honored to announce Dr. Gerald Chan as the winner of the 2016 Visionary in Life Sciences CABS K. Fong Special Award. Dr. Chan has made life-long contributions in cultivating a generation of successful entrepreneurs and life sciences companies. The spirit of generosity and outstanding leadership embodied by Dr. Chan will transpire CABS and beyond. As the president of CABS, I am extremely proud to work with colleagues in our eight executive committees and offices, whose passion and dedication make CABS a better organization every day. I am also truly appreciative of our devoted members and sponsors, who have and continue to support CABS. Thank you for joining us. I hope you enjoy today s program. With warm regards, Jiangwen Majeti, CABS President 9

10 Shooting for the Stars Membership Overall Membership MBA 5% J.D. 5% Medical Devices, Instrument & Diagnostics 22% Bachelor's 5% By Degree Master's 13% By Industry BioPharmaceutical 49% CRO 6% Ph.D. 72% Professional Services 7% Academic 16% Operations & Manufacturing 15% Others 3% Scientist 69% Venture Capital 6% Law 6% By Position By Function Sales & Marketing 12% Academic Faculty 7% Executives 12% Management Consulting 4% Academic 14% R&D 43% Ph.D. Student / PostDoc 9% LinkedIn Membership Our LinkedIn Group has also seen continued growth over the last year and is becoming an increasingly important component in our mission of promoting public awareness of the life science industry, encouraging business opportunity and exchange, and serving as a bridge for the life science industry throughout the Asia Pacific. URL: Membership as of April 20, 2016: 618 By Seniority By Industry CXO 5% Owner 6% Manager 8% Director 8% Other 16% Entry 19% Senior 38% Higher Education 3% Chemicals 3% Medical Devices 3% Other 17% Research 14% Pharmaceuticals 18% Biotech 42% 10

11 BIOPACIFIC CONFERENCE TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY Inaugural BioPacific Partnering Forum The 2016 BioPacific Conference brings together leaders in the life sciences community from the Pacific Rim and the United States. In order to further facilitate the interactions including project introduction and talent recruitment between our attendees and our sponsors, we are introducing a two-day BioPacific Partnering Forum in conjunction with our conference this year. Our Sponsors: Three major sponsors: Ningbo Kangtaibo Technology Development Co. Ltd & Ningbo Hangzhou Bay New Zone Zibo National High-tech Industrial Development Zone Chengdu Kanghong Pharmaceuticals Group All sponsors and exhibitors of 2016 BioPacific Conference How to Participate: Complimentary for all attendees, sponsors and exhibitors of the 2016 BioPacific Conference Sign up at icc@cabsweb.org to schedule one-on-one meetings Please indicate which sponsor you would like to meet along with your CV and project ppt as appropriate If you are interested in meeting other sponsors, please let us know When and Where: May 7 from 9am 6pm Onsite at the 2016 BioPacific Conference One-on-one meeting May 8 from 10am 5pm Hanqi Investment Inc. (1633 Bayshore Hwy, Burlingame, CA 94010) Featured presentations from three major sponsors; brief presentations from other participating sponsors Followed by one-on-one meeting About the Inaugural BioPacific Partnering Forum: Enable one-on-one discussions with BioPacific Conference sponsors and exhibitors Learn more about incentives for entrepreneurs at Ningbo Kangtaibo Technology Development Co. Ltd, Ningbo Hangzhou Bay New Zone and Zibo National High-tech Industrial Development Zone Access to senior management of Chengdu Kanghong Pharmaceuticals Group for talent recruitment and project collaboration 11

12 Shooting for the Stars BIOPACIFIC CONFERENCE 2016 AGENDA Shooting for the Stars Entering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine 8:00am 8:45am Registration Morning Session I: Welcome & CABS K. Fong Award Session Chair: Wentao Zhang, Ph.D. 8:45am 8:50am 8:50am 9:00am 9:00am 9:10am 9:10am 10:00am 10:00am -10:20am Welcome Remarks Cheni Kwok, Ph.D., CLP, President-Elect of CABS & 2016 BioPacific Conference Organizing Committee Chair State of the Society Jiangwen Majeti, Ph.D., MBA, President of CABS CABS K. Fong Special Award: Visionary in Life Sciences Presenter: Kenneth Fong, Ph.D., Chairman, Kenson Ventures Awardee: Gerald Chan, Sc.D., Co-Founder, Morningside Somewhere Between Science and Humanity Gerald Chan, Sc.D., Co-Founder, Morningside Break Morning Session II: Successful Business Models & Entrepreneurship Session Chair: Jessica Sun, M.D. & Gavin Lu, Ph.D. 10:20am 10:55am 10:55am 11:30am 11:30am 12:00pm M&A: An Insider s Perspective Hari Kumar, Ph.D., Ex-Chief Executive Officer & Board of Director, Adheron Therapeutics Vaccines: Lessons from the Oldest Class of Biologics Piers Whitehead, Executive Vice President & Chief Business Officer, PaxVax Life Sciences Parks in China: Growth and Trends Robert Lou, Manager Director, Ningbo Kangtaibo Technology Development Co. Ltd & Hui Zhang, Deputy Director, Ningbo Hangzhou Bay New Zone Investments and Partnership Branch 12

13 BIOPACIFIC CONFERENCE :00pm 1:00pm Lunch Break Afternoon Session I: Life Sciences Breakthroughs & Partnerships Session Chairs: Connie Sun, Ph.D. & Charlene Liao Ph.D. 1:00pm 1:30pm 1:30pm 2:05pm 2:05pm 2:40pm 2:40pm 3:15pm 3:15pm 3:45pm 3:45pm 4:05pm Chengdu Kanghong Biotech Co and Conbercept Jinqun Yin, MBA, Vice President, Chengdu Kanghong Pharmaceutical Group Immunotherapy: Past, Present and Future Mark Selby, Ph.D., Senior Director, Immuno-oncology, Bristol-Myers Squibb CRISPR/dCas9 Technology for Genome Manipulation and Disease Research Stanley Lei Qi, Ph.D., Assistant Professor, Department of Bioengineering and Department of Chemical and Systems Biology, Stanford University The Art of Partnering Darren Ji, M.D., Ph.D., MBA, Vice President and Global Head of Roche Partnering, Asia and Emerging Markets Key Trends and Case Studies: U.S. China Cross-Border Life Sciences Investment and Strategic Cooperation Charles Comey, J.D., Partner, Morrison & Foerster LLP Coffee break Afternoon Session II: Trends in BioPharmaceutical Development China & Global Considerations Session Chair: Shichang Miao, Ph.D. & Yang Tian, Ph.D. 4:05pm 5:20pm 5:20pm 5:50pm 5:50pm 5:55pm 5:55pm 6:00pm 6:00pm 6:45pm 6:45pm 7:15pm 7:15pm - 7:30pm Panel Discussion: BioPharmaceutical Development - China & Global Considerations (Moderator: Shichang Miao, Ph.D.) Xian-Ping Lu, Ph.D., Chief Executive Officer & Chief Scientific Officer, Chipscreen Biosciences Shawn Qian, Ph.D., Co-Founder, Chief Executive Officer & President, NeuPharma Xiaodong Yang, M.D., Ph.D., President and CEO, Apexigen Dan Zhang, M.D., Ph.D., Chairman & Chief Executive Officer, Fountain Medicine Development Ltd Claim Construction Before PTAB and the Courts Thomas L. Irving, J.D., Partner & Wen Li Ph.D., Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Introduction to Medicilon Cheni Kwok, Ph.D., CLP, Senior Consultant, Medicilon and Managing Partner, Linear Dreams Introduction to Pharmaron Connie Sun, Ph.D., Senior Vice President, Business and Corporate Development, Pharmaron Networking Session Dinner Burma, the Golden Land. A Photographic Journey in Support of Global Health Steven Adams, DVM, Ph.D., Executive Director, Portfolio & Operations for Oncology Research Worldwide R&D, Pfizer Evening Session: US-China Cross-Border Healthcare Investment & Entrepreneurship Session Chair: Yan Wang, Ph.D. 7:30pm 9:00pm 9:00pm Panel Discussion: US-China Cross-Border Healthcare Investment & Entrepreneurship (Moderator: Alexis Ji Ph.D., MBA) Min Cui, Ph.D., Founding Partner & Managing Director, Decheng Capital Alexis Ji, Ph.D., MBA, Principal, WuXi Healthcare Ventures Shawn Lee, Ph.D., Vice-Chairman, Xinbang Pharmaceuticals; President & CEO, CPC Scientific Inc. Cheng Liu, Ph.D., Founder & Chief Executive Officer, Eureka Therapeutics Vincent Liu, Ph.D., Senior Consultant, Wanbang BioPharmaceutical, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. Yuwen Liu, Founding Partner, Bohe Angel Fund James Zhao, M.D., Founding Partner, LYFE Capital Darren Ji, M.D., Ph.D., MBA, Vice President and Global Head of Roche Partnering, Asia and Emerging Markets Jennifer Hu, Ph.D., Venture Partner, Qiming Venture Partners Conference Adjourned * The official working language of the conference is English 13

14 Shooting for the Stars SPEAKERS Gerald Chan, Sc.D. Co-founder Morningside Group Winner of 2016 CABS K. Fong Special Award Visionary in Life Sciences Somewhere between Science and Humanity Bio Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments. In the life science sector, Morningside focuses on startup biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses (BioVex, DNAtrix), cancer vaccines (Aduro), modified cytotoxic agents (Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo). Investments in the infectious disease area include novel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Other investments cover the therapeutic areas of metabolic diseases (CVI), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognoa), and rare orphan diseases (Stealth, Apellis), as well as molecular diagnostics (ACD), drug delivery (Medtrum, Incarda) and medical devices (ViOptix, Kona, Excera). Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean s Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong. Gerald received his BS and MS degrees in engineering from UCLA, his Master s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health. 14

15 SPEAKERS BIOPACIFIC CONFERENCE Hari Kumar, Ph.D. Ex-Chief Executive Officer & Board of Director Adheron Therapeutics Inc. M & A; an Insider s Perspective Abstract: Having led two M & A transactions in the last 4 years, my presentation will look at some of the key factors that influence and ultimately bring about a successful transaction. I will use the two events as case studies and try and provide the audience an understanding of how some of the key decisions that were made help to bring about success. We will also look at some of the learnings from the case studies and these in turn should help the audience navigate their own issues. The presentation will try and provide, as near as possible, a template to a successful transaction. Bio Hari Kumar is a Pharmaceutical executive with over 25 years of experience in the industry. Hari started his Pharmaceutical career at Roche, first in basic research, subsequently moving to sales and marketing, lifecycle management and finally to business development. During the period of 1996 through 1999, Hari was the European Marketing Director for Eisai Ltd before returning to Roche in 1999 as Global Head of Transplant Immunosuppressives. He moved to Amira Pharmaceuticals Inc in 2007 as Chief Business Officer and after Amira s acquisition in 2011, was Chief Executive Officer of Panmira Pharmaceuticals LLC for two years. In 2013 Hari became Chief Executive Officer of Adheron Therapeutics, Inc which he led until the successful acquisition of the company. In his time, Hari has overseen the launch of the immunosuppressive, CellCept, the Alzheimer s drug, Aricept and gastric ulcer drug, Aciphex. He was also involved in guiding cross functional teams at Roche for the Transplantation franchise which resulted in the growth of the products in the franchise to achieve billion dollar sales. In his role as lead in-licensing person for inflammation at Roche, he identified and partnered valuable products that have enhanced Roche s portfolio. He was instrumental in partnerships with Isotechnika, Biotie, Biocryst and Actelion. Experience in almost all aspects of the pharmaceutical industry has given Hari a unique understanding on what makes a successful pharmaceutical business. At Amira, Hari led the process that resulted in the acquisition by Bristol Myers Squibb in His second big acquisition came as CEO and Board member of Adheron Therapeutics, Inc, which was bought by Roche. He has now led two acquisitions which have resulted in over a billion dollars in returns to investors. Having trained as an immunologist at University College London where he completed his PhD under the supervision of Prof N A Mitchison, Hari completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK. 15

16 Shooting for the Stars SPEAKERS Piers Whitehead Executive Vice President & Chief Business Officer PaxVax Vaccines: Lessons from the Oldest Class of Biologics Abstract: Vaccines are one of the oldest medical interventions and have had a huge impact on human health, but historically have been something of a backwater for the broader biopharmaceutical industry. What lessons might the vaccine industry have for the sector more broadly? And how does one small company, PaxVax, intend to compete and win in a mature industry structure? the Global Alliance for Vaccines and Immunization (GAVI), UNICEF, and several private sector pharmaceutical and biopharmaceutical companies. Mr. Whitehead has published extensively on the vaccine industry and related public policy matters and holds an A.B. from Oriel College, Oxford University, England. Bio Mr. Whitehead joined PaxVax in early 2013 and brings 20 years of experience in the vaccines and biopharmaceutical industries. He previously served as Vice President of Corporate Development for Paris based Neovacs. Prior to that, he was Vice President of Corporate and Business Development for vaccine company, VaxGen. At VaxGen, he negotiated several important partnerships and led the company s commercial strategy, resulting in the award of a nearly one billion dollar Project Bioshield Act contract. He also spent 10 years at Mercer Management Consulting, where he headed the San Francisco office and led marketing, strategy, and manufacturing projects for clients including 16

17 BIOPACIFIC CONFERENCE SPEAKERS Robert Lou 楼 国 强 Manager Director 总 经 理 Ningbo Kangtaibo Technology Development Co.,Ltd 宁 波 康 泰 博 科 技 发 展 有 限 公 司 Presentation title: Life Sciences Parks in China: Growth and Trends Abstract: Mr Robert Lou will provide a historical prospective of the formation and growth of Chinese life sciences parks, an overview on the distribution of life sciences parks throughout China as well as an analysis of the resources provided by the parks to address the needs of the life sciences industry. Mr Lou s presentation will also discuss how life sciences parks can further improve their competitive advantages to tailor to the needs of the industry. 中 国 生 物 医 药 科 技 园 区 成 长 和 园 区 建 设 的 思 考 和 探 索 演 讲 者 通 过 对 中 国 生 物 医 药 园 区 的 形 成 背 景, 中 国 生 物 医 药 行 业 及 园 区 的 分 布 特 点 等 对 生 物 医 药 产 业 园 概 况 进 行 介 绍 和 分 析, 从 医 药 企 业 对 生 物 医 药 园 区 的 需 求 等 角 度, 对 如 何 提 升 园 区 竞 争 力 进 行 思 考, 并 提 出 宁 波 杭 州 湾 生 命 科 技 园 关 于 技 术 基 础 设 施, 服 Bio Robert Lou is the founder and managing director of Ningbo Kangtaibo Technology Development Co.,Ltd, which is constructing and operating BioVillage, a life science park with 250,000 m 3 building area in Ningbo Hangzhou Bay New Zone. In 2010, he founded Hangzhou Honor Investment, an investment company mainly focusing on early stage companies investment in life science field. Before that, he had been engaged in international containerized transportation for more than 10 years and tourism industry for more than 5 years. Robert Lou got a bachelor degree majoring in Nuclear Engineering in 1987, and a master degree majoring in Enterprise Management in 1990 from Shanghai Jiaotong University. Robert Lou is the early investor of Pharmaron. 务 体 系 建 设 和 发 展 等 的 理 念, 希 望 和 与 会 者 进 行 分 享 和 探 索 17

18 Shooting for the Stars SPEAKERS Hui Zhang 张 辉 Deputy Director, Investment and Partnership Branch 投 资 合 作 局 副 局 长 Ningbo Hangzhou Bay New Zone 宁 波 杭 州 湾 新 区 Introduction to Ningbo Hangzhou Bay New Zone Abstract: Introduction to Ningbo Hangzhou Bay New Zone Mr Hui Zhang will give an introduction to Ningbo Hangzhou Bay New Zone, highlighting the zone s key achievements. 有 关 宁 波 杭 州 湾 新 区 : 宁 波 杭 州 湾 新 区 地 处 中 国 经 济 最 发 达 的 长 三 角 地 区, 于 2010 年 2 月 23 日 正 式 成 立 新 区 是 目 前 中 国 正 在 大 力 推 进 建 设 的 一 带 一 路 的 重 要 节 点, 也 是 宁 波 港 口 经 济 圈 建 设 的 重 要 组 成 部 分 区 内 分 别 设 有 国 家 级 经 济 技 术 开 发 区 和 国 家 级 出 口 加 工 区 目 前 新 区 初 步 形 成 了 产 业 新 城 湿 地 三 大 功 能 板 块 : 制 造 业 区 块 已 建 成 面 积 达 50 平 方 公 里, 累 计 落 户 工 业 企 业 项 目 435 个, 投 产 企 业 331 家, 集 聚 了 德 国 大 众 德 国 博 世 荷 兰 联 合 利 华 等 13 家 世 界 500 强 企 业 的 投 资 项 目 19 个 重 点 发 展 汽 车 及 其 关 键 零 部 件 通 用 航 空 生 命 健 康 产 业 智 能 电 气 高 端 装 备 和 高 性 能 新 材 料 产 业 商 务 新 城 区 27 平 方 公 里 正 在 建 设, 五 年 来, 大 型 城 市 综 合 体 五 星 级 酒 店 高 等 院 校 高 等 级 医 院 科 技 研 发 孵 化 基 地 城 市 广 场 等 一 批 功 能 性 项 目 相 继 落 户 建 成 新 区 还 拥 有 43.5 平 方 公 里 的 湿 地 休 闲 区, 宁 波 杭 州 湾 湿 地 是 东 亚 最 大 的 咸 淡 水 海 滩 湿 地 之 一 2005 年 在 全 球 环 境 基 金 (GEF) 和 世 界 银 行 支 持 下 启 动 建 设, 目 前 4.3 平 方 公 里 核 心 区 已 建 成 开 放 并 晋 升 为 国 家 级 湿 地 公 园 生 物 医 药 和 大 健 康 产 业 作 为 宁 波 杭 州 湾 新 区 的 主 导 产 业 之 一 为 打 造 百 亿 级 产 值 产 业 集 群, 宁 波 杭 州 湾 新 区 规 划 10 平 方 公 里 建 设 宁 波 杭 州 湾 国 际 生 命 健 康 产 业 园 依 托 复 旦 大 学 研 究 院 科 创 中 心 通 济 产 业 园 博 士 后 科 研 工 作 站 等 平 台, 围 绕 生 物 制 药 医 疗 器 械 健 康 产 品 健 康 休 闲 等 领 域, 打 造 成 为 长 三 角 地 区 重 要 的 生 命 健 康 产 业 基 地 目 前, 宁 波 杭 州 湾 国 际 生 命 健 康 产 业 园 已 集 聚 了 康 龙 化 成 双 成 麟 沣 正 力 安 拓 等 17 家 企 业 园 区 将 依 托 高 端 装 备 制 造 和 生 命 健 康 产 业 基 础, 重 点 引 进 生 物 制 药 医 疗 器 械 和 大 健 康 产 业 企 业, 包 括 新 药 研 发 服 务 医 药 制 造 医 疗 器 械 设 备 生 产 健 康 食 品 及 功 能 性 化 妆 品 生 产 等 项 目 宁 波 杭 州 湾 国 际 生 命 健 康 产 业 园 对 接 国 际 优 秀 生 命 健 康 产 业 项 目 的 优 势 十 分 明 显, 包 括 区 位 及 交 通 优 势 土 地 空 间 优 势 市 场 优 势 人 力 资 源 优 势 自 然 环 境 优 势 政 策 体 制 优 势 等 此 外, 为 大 力 发 展 生 命 健 康 产 业, 支 持 生 命 健 康 企 业 的 发 展, 打 造 国 际 一 流 生 命 健 康 产 业 园, 宁 波 杭 州 湾 新 区 为 落 户 项 目 制 定 一 对 一 的 支 持 政 策 Bio Mr Hui Zhang is the Deputy Director of Ningbo Hangzhou Bay New Zone Investments and Partnership. Mr Zhang supports the Director and is responsible for two branches of industrial investment: First branch and Second Branch (International Investment Branch). Mr Zhang is responsible for promoting international business development for the sectors including automobile and parts; civil aviation, life sciences and wellness as well as biopharmaceuticals. 18

19 SPEAKERS BIOPACIFIC CONFERENCE Jinqun Yin Vice President Chengdu Kanghong Pharmaceutical Group Co., Ltd Chengdu Kanghong Biotech Co and Conbercept Abstract: Located in Chengdu, China, Chengdu Kanghong Biotech Co is one of the 7 subsidiaries of the 20-year-old Chengdu Kanghong Pharmaceutical Group Co. It is a leading biopharmaceutical company in China, which specializes in the discovery, development, manufacture, and marketing of innovative biologics. Its first biologics, Conbercept, is a novel anti-vegf (Vascular Endothelial Growth Factor) agent. This is a recombinant fusion protein. including the domain 2 of VEGF receptor (VEGFR)-1, domain 3 and 4 of VEGFR-2, plus human IgG Fc fragment. Conbercept has high VEGF binding affinity, is a 100% humanized protein, and can target multiple VEGF subtypes, including VEGF-A, VEGF-B and PIGF. After 5 clinical trials were successfully finished, Conbercept Ophthalmic Injection was approved to treat Neovascular Age-Related Macular Degeneration (wet AMD) by the CFDA in December, 2013, and launched in China market in March, Now other indications in ophthalmology, such as Choroidal Neovascularization Secondary to Pathological Myopia (pmcnv), Diabetic Macular Edema (DME), and Retinal Vein Occlusion(RVO) are under late-stage clinical development. Conbercept has demonstrated well-tolerated safety profile and superior efficacy, and has been well received in the Chinese market. Holding strong global IP protection, Chengdu Kanghong Biotech is actively pursuing expansion of Conbercept into global market. Meanwhile, Chengdu Kanghong Biotech has a strong pipeline in R&D including KH903 for the treatment of different tumors, and KH906 for the treatment of neovascularization corneal diseases. Bio Jinqun Yin, MBA is the VP of Chengdu Kanghong Pharmaceutical Group Co, Ltd and Head of Marketing, Sales, Medical Affairs, Government Affairs, and Enterprise Brand Communication. He is a graduate from Beijing International MBA at Peking University and has15 years working experience in multinational pharmaceutical companies, starting in Johnson & Johnson as a medical representative through regional director in China. In early 2008, joined Bayer Pharmaceuticals as the director of national antithrombotic business unit, led a team to successfully launch Bayer s global strategic product Xarelto (Rivaroxaban ) in China and uplifted the classic Bayaspirin to the best in Chinese market. In 2011, led and implemented Bayer s Chinese Growth Strategy, working as the director of emerging market development division. Established new mode of integral promotion of all products and expanded sales to 4th and 5th line cities in China. After Conbercept was launched in the market, it broke several records of marketing and sales in Chinese pharmaceutical industry. Due to its excellent profile of safety and efficacy in clinic and great contribution to the community in China, Conbercept was awarded one of the best innovative drugs of clinical value by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and the People Net in China. In the past 10 years, only 3 drugs were selected and awarded from all drugs which were launched in the past 10 years in China. 19

20 Shooting for the Stars SPEAKERS Mark Selby, Ph.D. Senior Director, Immuno-oncology Bristol-Myers Squibb Immunotherapy: Past, Present and Future Abstract: The concept of antibody immunotherapy for cancer originated in the laboratory of Dr. James Allison in a paper published in It took nearly 20 years to bring antibody drugs to patients and to change the treatment paradigm from chemotherapy to include immunotherapy. While anti- PD-1 and anti-pd-l1 antibodies are leading this revolution by promoting deep and durable responses in various cancers, much is yet to be done to ensure greater response rates and expand the repertoire of responsive malignancies. I will highlight the direction of the pharmaceutical industry to meet this challenge and note learnings from in vivo mouse tumor models. Focusing on antibody therapies, I will highlight new targets and therapies which may make cancer a more manageable disease with more options for patients. Bio I completed my graduate studies in the UCSF laboratory of Dr. William Rutter where I cloned and sequenced the Nerve Growth Factor cdna. I also determined the mouse NGF genomic organization and studied proteolytic processing of the NGF precursor protein. I completed my post-doctoral research in the laboratory of Dr. Matija Peterlin, also at UCSF. Here I researched regulation of HIV LTR transcription focusing on the TAT transcriptional activator and its interaction with the TAR sequence at the 5 end of HIV transcripts. Thereafter I joined the Vaccines group at Chiron, working with Michael Houghton on HCV and then with Jeffery Ulmer on DNA vaccination. In 2001 I left Chiron and joined Alan Korman at Medarex. Here we studied the anti-ctla-4 antibody, ipilimumab. Later, with other colleagues, we developed the nivolumab anti-pd-1 antibody and several other fully human antibodies for oncology. 20

21 SPEAKERS BIOPACIFIC CONFERENCE Stanley Lei Qi, Ph.D. Assistant Professor Stanford University CRISPR/dCas9 technology for genome manipulation and disease research Abstract: The bacterial CRISPR/Cas9 system offers an approach for RNA-guided genome manipulation in mammalian cells, useful for interrogating and profiling gene functions. We have developed a versatile non-mutagenic genome manipulation platform based on the nuclease-dead Cas9 (dcas9), named CRISPR interference (CRISPRi), which enables complex orthogonal and inducible transcriptional regulation. Using these orthogonally acting dcas9s, we show that the platform enables robust activation and repression of multiple endogenous genes in the genome. We demonstrate the system allows high-throughput whole-genome screening of gene function, and show its uses for modeling diseases such as cardiomyopathy using human induced pluripotent stem (ips) cells and ips-derived cardiomyocytes. We compare the use of CRISPRi and CRISPR for different purpose of gene manipulation, and highlight the interesting features comparing gene regulation to gene editing. Finally, we show the use of dcas9 for other genomic studies including capturing the dynamics of chromosome loci in living mammalian cells. The talk will highlight the development and use of CRISPR and dcas9 for non-editing based genome manipulation and its potential applications. Bio Dr. Lei (Stanley) Qi is an assistant professor in the Department of Bioengineering, and of Chemical and Systems Biology. He is also faculty fellow in the interdisciplinary Institute for Chemistry, Engineering, and Medicine for Human Health (ChEM-H). He obtained his Ph.D. in Bioengineering from UC Berkeley, and started his lab as Systems Biology Faculty Fellow at UCSF. He is interested in developing novel technologies for cancer and immunology disease research, and Systems and Synthetic Biology. He is one of the major pioneers in the CRISPR technology for targeted genome engineering in mammalian cells. Different from most developers of the CRISPR tools, he has developed a series of gene regulation and imaging technologies, including CRISPR interference (CRISPRi), CRISPR imaging, and high-throughput CRISPR screening. He also worked in the fields of Synthetic Biology, and developed methods to generate synthetic noncoding RNA regulators of transcription, translation, and as molecular sensor for chemicals and intracellular proteins. 21

22 Shooting for the Stars SPEAKERS Darren Ji, M.D., Ph.D., MBA Vice President and Global Head Roche Partnering Asia and Emerging Markets The Art of Partnering Abstract: A successful partnering is an art. It takes many components to build one. Solid science, differentiated benefits, trust, story, terms, creativity, right people and timing. All these great elements have to come together in a coherent way to date, to dance and to marry. On this topic Darren shares his experiences and perspectives from both sides as a corporate executive and as a past entrepreneur. Darren previously served as a Board Director, and Shanghai regional leader of the BayHelix Group, a global organization of Chinese business leaders in life sciences. Darren obtained his medial degree from China Medical University, China; a PhD from the University of Sheffield, UK; and an MBA from University of Chicago, USA. Bio Dr. Darren Ji is currently Vice President and Global Head, Asia and Emerging Markets Partnering, Roche. Darren was previously President and CEO of NPBiosciences, a biotech company based in Singapore. Prior to that Darren founded and served as CEO of PharmaLegacy Laboratories, which is a Shanghai-based Contract Research Organization specializing in preclinical pharmacology services. Darren spent 11 years at the Procter & Gamble Company with progressive responsibilities in drug research and development, and as director of bioscience business development in East Asia. 22

23 SPEAKERS BIOPACIFIC CONFERENCE Charles Comey, J.D. Partner Morrison & Foerster Key Trends and Case Studies: U.S. China Cross-Border Life Sciences Investment and Strategic Cooperation Abstract: Morrison & Foerster Corporate Partner Chuck Comey will overview recent market data on China-US life sciences strategic / VC investment and highlight interesting issues from a two recent cases, the first a corporate VC investment / strategic alliance, the second an acquisition, involving Chinese companies partnering or acquiring U.S. life sciences companies. Bio Charles Comey is an M&A and corporate finance partner in the firm s Palo Alto office. Mr. Comey s practice experience includes working on the ground in China and Japan for 16 years. He advises clients on mergers and acquisitions, venture capital and private equity financings, and joint ventures and strategic alliances in the technology, consumer and life sciences sectors. Beginning in 1994, Mr. Comey was seconded by Morrison & Foerster to the legal department of a major Japanese trading company, and thereafter was resident for nine years in Morrison & Foerster s Tokyo office, where he specialized in cross-border mergers and acquisitions and strategic alliances. Before relocating to Silicon Valley in July 2010, Mr. Comey opened and served as managing partner of the firm s Shanghai office from Mr. Comey is admitted to practice in California and is a member of the California and American bar associations. He speaks and reads Mandarin Mr. Comey is recommended as a leading lawyer by Chambers Global 2015 (PE expert based abroad China focus, PE foreign expert US focus), Chambers USA 2014 and 2015 (California Corporate/M&A: Deals in Asia), Legal 500 Asia Pacific 2015 (Corporate and M&A Foreign Firms), Legal 500 US 2013, Chambers Asia 2011, IFLR , PLC Which lawyer? 2010 and Euromoney s Expert Guides. 23

24 Shooting for the Stars SPEAKERS Thomas L. Irving, J.D. Partner Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Wen Li, Ph.D. Associate Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Claim Construction Before PTAB and the Courts Abstract: Tom Irving and Wen Li will discuss how to use fundamentally sound principles to prepare and prosecute a U.S. biopharmaceutical patent application to enhance the chances of obtaining a desired claim construction that is appropriate to business objectives and with a view to preempting potential issues in district court litigation and PTAB proceedings. With the rising tension between the district courts and PTAB standards in claim construction presenting important claim construction developments for practitioners right now, the take-home message remains to lay the groundwork in the specification (the single best guide to the meaning of a claim term) for the desired claim construction(s) to withstand both district court and PTAB challenges and yet also cover the reasonably foreseeable competitive products. 24

25 BIOPACIFIC CONFERENCE Bio of Thomas L. Irving Tom Irving has more than 40 years of experience in the field of intellectual property law. His practice includes America Invents Act (AIA) post-grant proceedings, due diligence, counseling, patent prosecution, and reissue and reexamination. He counsels clients on a wide range of mainly pharmaceutical matters, including pre-litigation, Orange Book listings of patents covering FDA approved drugs, infringement issues, enforceability and validity analysis, and litigation. A significant portion of Mr. Irving s current practice is focused on AIA post-grant proceedings, including how to enhance the strength of patents in the pharmaceutical space to protect against post-grant challenges. He has served as lead counsel in numerous patent interferences, reissues, and reexaminations; as counsel in numerous AIA post -grant proceedings; and as an expert witness in patent litigation. Mr. Irving has been involved in every facet of several U.S. district court litigations, thus enhancing his ability to render advice in due diligence, enforceability, infringement, validity, and patent prosecution areas. Mr. Irving has served for more than 25 years as principal teacher of the Patent Resources Group (PRG) Chemical Patent Practice course, a comprehensive U.S. chemical patent law course taught two times a year, and he coauthors the multi-volume treatise used in the course. In addition, Mr. Irving originated PRG s Orange Book and Due Diligence courses, which help prepare patent owners, through effective application drafting and prosecution, to withstand the rigors of AIA s inter partes review (IPR) and post-grant review (PGR). He presents analyses of U.S. Court of Appeals for the Federal Circuit patent decisions for many state bar association groups and has spoken at numerous national bar association meetings such as the American Intellectual Property Law Association (AIPLA), Intellectual Property Owners Association, and American Bar Association. Mr. Irving has lectured at many law schools in both the United States and China. He also has lectured at the Cold Spring Harbor National Laboratory graduate school, the Patent Office of the State Intellectual Property Office (SIPO) of the People s Republic of China, and has presented nearly 50 Strafford Webinars on patent law topics, including a number that deal with AIA s post-grant proceedings. Outside of the patent law field, he has been involved in public health and safety issues related to the preparation of Citizen Petitions before the FDA for pharmaceutical matters. Bio of Wen Li Wen Li focuses her practice on U.S. and international patent prosecution in the pharmaceutical and chemical areas. Her experience includes managing world-wide patent portfolios for important pharmaceutical companies. Her practice also includes patent litigation, due diligence investigations, patentability/infringement opinion drafting, and client counseling. Dr. Li has an extensive scientific background and experience in pharmaceutical research. Before joining the firm, she worked for a number of years as a senior/principal medicinal chemist in a biopharmaceutical company where she gained experience in designing and synthesizing small molecule antagonists for GPCRs and Integrin receptors. Dr. Li was a named inventor in several patents in these fields. In addition to having an in-depth understanding of pharmaceutical chemistry, she also has a deep understanding of concepts concerning bioavailability, which include Cmax, AUC, and ADME. She applies her background by working with expert witnesses, particularly in areas involving XRPD, HPLC, and NMR. Dr. Li s research background includes synthesis of unnatural amino acids and macrocyclics, as well as the study of secondary structures of peptidomimetics. Dr. Li is also familiar with a wide range of chemistry principles, which include physical chemistry, peptide chemistry, polymer chemistry, and transition-metal catalysis chemistry. SPEAKERS 25

26 Shooting for the Stars SPEAKERS Panel Discussion: BioPharmaceutical Development - China & Global Considerations Bio Dr. Shawn Qian is a Co-Founder, President & CEO at NeuPharma, a biopharmaceutical company dedicated to the research and development of innovative medicines for unmet medical needs. Before co-founding NeuPharma, Dr. Qian was an Associate Director of Medicinal Chemistry and Program Leader at Cytokinetics, where he was responsible for the medicinal chemistry efforts on the discovery of novel therapeutics for the treatment of cancer, asthma and cardiovascular diseases. Prior to joining Cytokinetics, Dr. Qian was a NSERC post-doctoral fellow at Harvard University. Dr. Qian received his Ph.D. in Organic Chemistry from University of Alberta, Canada in 2000, and B.Sc. in Chemistry from Nanjing University, China in He is an author of 42 papers and an inventor of over 50 patents. Shawn Qian, Ph.D. Co-Founder, Chief Executive Officer & President, NeuPharma Bio Dr. Xian-Ping Lu founded Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 15 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D (subsidiary of L Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals. Xian-Ping Lu, Ph.D. Chief Executive Officer & Chief Scientific Officer Chipscreen Biosciences Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University. With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 80 peer-reviewed papers in prestigious journals including Nature and Science. He is the lead inventor of over 80 patented inventions in areas of small molecule therapeutics. 26

27 BIOPACIFIC CONFERENCE Dan Zhang, M.D., Ph.D. Chairman & Chief Executive Officer Fountain Medicine Development Ltd Bio Dr. Dan Zhang has more than 15 year of drug development experience. He is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with operations in South East Asia, China, Armenia and USA. With 400 employees, FMD runs phase I/II/III/IV operations with full support of regulatory affairs, data management and biostatistics, EDC and pharmacoeconomics operations. FMD has 70 employees in Philadelphia of USA and have filed 15 NDAs in last 2 years and obtained approval for 10 NDA applications. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp., a member of Quintiles Executive Operation Committee, and was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc. Over last the 15 years, Dr. Zhang has provided services for the government and academic institutions in China. He is a member of grant review committee for National Key Drug Development Fund jointly managed by the Ministry of Science & Technology (MOST) and the National Health and Family Planning Commission of China (NHFPC). He chaired the Bayhelix CFDA working committee and works with the agency on the development of technical guidelines. He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He is the senior consultant to Chinese Academy of Medical Sciences and Peking Union Medical College. He was also a visiting professor at the Harbin Medical University of China, Nankai University and Science and Technology University of South China. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA), and a board of director of Bayhelix. He is the Secretary-General of the Association of Thousand Talents Program. SPEAKERS Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance. 27